Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics | 05.05.2020
Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced an agreement to collaborate and develop novel orally-delivered protein therapeutics (biologics), incorporating proprietary technologies developed by each of the partners. The collaboration combines Elasmogen’s soloMER™ technology, small (11 kDa) single-chain binding domains that can be rapidly re-formatted to generate super-neutralizers (bivalent, […]
Elasmogen Ltd to deploy their soloMER technology platform to develop tools to combat COVID-19 | 29.04.2020
29th April 2020; Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) are to collaborate with the University of Aberdeen as a partner on a Scottish Government research award of almost £1 M to tackle COVID-19. Current diagnostic testing for COVID-19 so called RT-PCR for infectious agents, whilst accurate is complex to perform, suited to centralised laboratories, takes […]
Elasmogen featured in Biotechnology and Biological Sciences Research Council Spinout report | 26.02.2020
Elasmogen has been featured in BBSRC’s report highlighting a few spinout companies that exemplify BBSRC investments in research.
Elasmogen nominated for Innovative Collaboration award with Almac Discovery | 24.01.2020
Elasmogen has been nominated for a Life Science Award with Almac Discovery in the Innovative Collaboration category. The finalists in the Innovative Collaboration award, sponsored by @MarksClerkScot are announced! They are @ElasmogenLtd , @iCAIRD_Scot , and @MedtronicUK . Find out who wins at #ScotLiSciAwards on 19 March – tickets available at https://t.co/z5f5tnBLNS pic.twitter.com/9Q7SOYezme — LifeScienceAwardScot […]
Elasmogen Secures £2 M Funding | 13.01.2020
Funding from Deepbridge Capital will support development of next generation biologics January 10th 2020: Aberdeen, Scotland: Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announced it has secured follow-on equity investment from Deepbridge Capital totalling £2 M, taking Deepbridge’s total investment in Elasmogen to £3.15 M. The funding will be used […]
Elasmogen technology featured in The Times news | 13.12.2019
We are delighted that The Times has featured Elasmogen in an article titled ‘Ruthless killers? Shark antibodies are latest weapon in fight against cancer‘.
Elasmogen featured in CONVERGE podcast | 19.11.2019
Elasmogen’s CEO, Caroline Barelle is featured in Converge’s podcast where she discusses her business journey.
Elasmogen CEO Caroline Barelle featured in news outlets as a leader in biotech space | 05.11.2019
CIOLook, is currently running a special edition on most prominent women leaders and Elasmogen’s CEO, Caroline Barelle has given an interview giving her perspective on leadership in the biotech industry. You can read the profile here. BioBeat has featured Caroline Barelle in their report 50 Movers and Shakers in BioBusiness 2019 which showcases the trailblazers and […]
Caroline Barelle featured in Insights Success | 03.07.2019
Elasmogen’s CEO Dr Caroline Barelle has been featured in Insight Success special edition Successful Women Making a Difference in Biotech. The article can be read here. Dr. Caroline Barelle: A Leader in Biotechnology Driving Innovation in Biologics Drug Development
Elasmogen CEO Caroline Barelle named one of top 20 women in leading biotech roles in Europe | 21.05.2019
Biotech media outlet Labiotech.eu which covers the European Biotech industry, has today, 21 May 2019, listed Elasmogen CEO, Dr Caroline Barelle among top 20 women in leading biotech roles in Europe. The full article can be found at https://labiotech.eu/tops/women-leaders-biotech-europe/ -ENDS-